Edgar E. Lara‐Ramírez

Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies

Isidro Palos, Edgar E. Lara‐Ramírez, Julio Cesar López-Cedillo et al. · Molecules · 2017 · 54 citations · Full text

Circulating miR‐146a, miR‐34a and miR‐375 in type 2 diabetes patients, pre‐diabetic and normal‐glycaemic individuals in relation to β‐cell function, insulin resistance and metabolic parameters

R.E. García-Jacobo, Edith Elena Uresti‐Rivera, Diana Patricia Portales‐Pérez et al. · Clinical and Experimental Pharmacology and Physiology · 2019 · 47 citations

An in vitro and in vivo evaluation of new potential trans -sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method

Edgar E. Lara‐Ramírez, Julio Cesar López-Cedillo, Benjamín Nogueda‐Torres et al. · European Journal of Medicinal Chemistry · 2017 · 43 citations · Full text

Trypanosoma Cruzi, Medicinal Chemistry, Parasitic Protozoa +11

Lipid Metabolism Alterations in a Rat Model of Chronic and Intergenerational Exposure to Arsenic

César Rivas-Santiago, Irma González-Curiel, Sergio Zarazúa et al. · BioMed Research International · 2019 · 41 citations · Full text

Trypanocidal Activity of Quinoxaline 1,4 Di-N-oxide Derivatives as Trypanothione Reductase Inhibitors

Karla Fabiola Chacón-Vargas, Benjamín Nogueda‐Torres, Luvia Enid Sánchez‐Torres et al. · Molecules · 2017 · 40 citations · Full text

Bioorganic Chemistry, Antiparasitic Agent, Quinoxaline 1,4 +20